Caribou Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRBU research report →
Companycariboubio.com
Caribou Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.
- CEO
- Rachel E. Haurwitz
- IPO
- 2021
- Employees
- 147
- HQ
- Berkeley, CA, US
Price Chart
Valuation
- Market Cap
- $196.87M
- P/E
- -1.43
- P/S
- 17.57
- P/B
- 1.87
- EV/EBITDA
- -1.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.21%
- Op Margin
- -1175.68%
- Net Margin
- -1189.14%
- ROE
- -100.13%
- ROIC
- -100.43%
Growth & Income
- Revenue
- $11.16M · 11.66%
- Net Income
- $-148,125,000 · 0.66%
- EPS
- $-1.59 · 3.64%
- Op Income
- $-136,194,000
- FCF YoY
- 22.36%
Performance & Tape
- 52W High
- $3.54
- 52W Low
- $0.96
- 50D MA
- $1.99
- 200D MA
- $1.93
- Beta
- 2.27
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on CRBU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 25, 26 | Kelly Timothy P | sell | 6,228 |
| Feb 20, 26 | Kelly Timothy P | other | 202,500 |
| Feb 20, 26 | Kelly Timothy P | other | 45,000 |
| Feb 24, 26 | Kelly Timothy P | sell | 3,147 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 45,000 |
| Feb 24, 26 | MCCLUNG BARBARA G | sell | 6,938 |
| Feb 20, 26 | MCCLUNG BARBARA G | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 202,500 |
| Feb 20, 26 | Khan Ruhi Ahmad | other | 45,000 |
| Feb 24, 26 | Khan Ruhi Ahmad | sell | 6,938 |
Our CRBU Coverage
We haven't published any research on CRBU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRBU Report →